[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100522287":3},{"organization":4,"armGroups":7,"interventions":31,"overallOfficials":42,"centralContacts":46,"locations":56,"responsibleParty":73,"collaborators":37,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":37,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":96,"overallStatus":59,"whyStopped":37,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Rennes University Hospital","OTHER",[8,15,19,23,27],{"label":9,"type":10,"description":11,"interventionNames":12},"DCS+","EXPERIMENTAL","Patient with subjective cognitive decline, prodromal condition of Alzheimer's disease",[13,14],"Diagnostic Test: fMRI","Diagnostic Test: CONFMEM",{"label":16,"type":10,"description":17,"interventionNames":18},"TCL-MA","Patient with mild neurocognitive disorder linked to Alzheimer's disease",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"MPdn","early-stage or de novo Parkinson's disease patients with no cognitive deficits",[13,14],{"label":24,"type":10,"description":25,"interventionNames":26},"TCL-MP","Patient with mild neurocognitive disorder linked to Parkinson's disease",[13,14],{"label":28,"type":29,"description":28,"interventionNames":30},"Healthy volunteers","ACTIVE_COMPARATOR",[13,14],[32,38],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"DIAGNOSTIC_TEST","fMRI","functional MRI",[9,28,20,16,24],null,{"type":33,"name":39,"description":40,"armGroupLabels":41,"otherNames":37},"CONFMEM","The aim of this paradigm is to identify the impact of cognitive conflict situations on recognition memory (the ability to judge whether or not a stimulus has been previously presented).",[9,28,20,16,24],[43],{"name":44,"affiliation":5,"role":45},"Pierre-Yves JONIN, PhD","PRINCIPAL_INVESTIGATOR",[47,53],{"name":48,"role":49,"phone":50,"phoneExt":51,"email":52},"marie-laure gervais, Phd","CONTACT","299282555","+33","marie-laure.gervais@chu-rennes.fr",{"name":44,"role":49,"phone":54,"phoneExt":51,"email":55},"299284321","pierreyves.jonin@chu-rennes.fr",[57],{"facility":58,"status":59,"city":60,"state":37,"zip":37,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"CHU Rennes","RECRUITING","Rennes","France","FR",{"type":64,"coordinates":65},"Point",[66,67],-1.67431,48.11109,{"lat":67,"lon":66},[70,72],{"name":71,"role":49,"phone":37,"phoneExt":37,"email":37},"Pierre-Yves JONIN",{"name":44,"role":45,"phone":37,"phoneExt":37,"email":37},{"type":74,"investigatorFullName":37,"investigatorTitle":37,"investigatorAffiliation":37,"oldNameTitle":37,"oldOrganization":37},"SPONSOR","100522287","network-based-biomarker-discovery-of-neurodegenerative-diseases-using-multimodal-connectivity-100522287",false,"NCT06080659","Network-based biOmarker Discovery of Neurodegenerative Diseases Using Multimodal Connectivity","NODAL","Inclusion Criteria:\n\n* For all participants:\n* French mother tongue\n* right-handed\n* with a level of education equal to or higher than the Certificat d'Études Primaires (Primary School Certificate)\n* Free of any medical or psychiatric condition likely to interfere with cognition (excluding diagnosis for patients)\n* Affiliated with a social security scheme\n* Having received oral and written information about the protocol and having signed a consent form to participate in this research.\n\nDCS+ group:\n\n\\- Meeting the diagnostic criteria for \"subjective cognitive decline-plus\" (Jessen criteria (Jessen et al., 2014).\n\nAlzheimer's patients \"Mild Cognitive Impairment due to Alzheimer's Disease,\" \"MCI-MA\":\n\n\\- Meeting the diagnostic criteria for \"Mild neurocognitive disorder due to Alzheimer's disease\" (criteria of (Albert et al., 2011))\n\nDe novo\" Parkinsonian patients, \"MPdn\":\n\n\\- Presenting with newly diagnosed (\"de novo\") Parkinson's disease and free of cognitive deficits (criteria of Postuma et al., 2015 (Postuma et al., 2015))\n\nParkinsonian patients with \"Mild Cognitive Impairment, \"MCI-MP\":\n\n\\- Presenting Parkinson's disease associated with \"mild neurocognitive impairment\" (criteria of Litvan et al., 2012 (Litvan et al., 2012))\n\nExclusion Criteria:\n\n* All participants (healthy volunteers and patients)\n* Contraindications to MRI :\n* Abdominal circumference + upper limbs sticking to the body \\> 200 cm;\n* Implantable pacemaker or defibrillator;\n* Neurosurgical clips;\n* Cochlear implants ;\n* Neural or peripheral stimulator;\n* Intra-orbital or encephalic metallic foreign bodies;\n* Endoprostheses fitted less than 4 weeks ago and osteosynthesis devices fitted less than 6 weeks ago;\n* Claustrophobia.\n* Pregnant or breast-feeding women;\n* Adults under legal protection (safeguard of justice, curatorship, guardianship), persons deprived of liberty.\n\nPatients only\n\n* Score \\>2 on the modified Hachinski scale (Hachinski et al., 2012)\n* Dementia according to McKhann criteria (McKhann et al., 2011)\n* Sensory deficit interfering with experimental tests\n\nHealthy volunteers only\n\n\\- Cognitive impairment (MoCA score \\\u003C 26)",true,"ALL","50 Years","80 Years",{"count":87,"type":88},120,"ESTIMATED","INTERVENTIONAL",[91],"NA","The aim of the NODAL clinical trial is to demonstrate the feasibility of new, low-cost, non-invasive biomarkers of neurodegenerative pathologies as early Alzheimer and Parkinson, based on the estimation of the multimodal connectome.",[94,95],"Alzheimer Disease, Early Onset","Parkinson Disease",[97],"connectome","2025-12-31",{"date":100,"type":101},"2026-01-05","ACTUAL",{"date":103,"type":101},"2023-11-06",{"date":105,"type":88},"2026-12",{"name":5,"class":6},1]